Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Research Letter

Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020

Sitanshu Sekhar KarComments to Author , Sonali Sarkar, Sharan Murali, Rahul Dhodapkar, Noyal Mariya Joseph, and Rakesh Aggarwal
Author affiliation: Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

Cite This Article

Abstract

We conducted 3 population-based cross-sectional surveys, at 1-month intervals, to estimate the prevalence and time-trend of severe acute respiratory syndrome coronavirus 2 infection in Puducherry, India. Seropositivity rate increased from 4.9% to 34.5% over 2 months and was 20-fold higher than the number of diagnosed cases of infection.

The magnitude of the ongoing pandemic of coronavirus disease (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not been fully assessed because most those infected have no or mild symptoms, and thus do not undergo viral nucleic acid or antigen testing (13). Determining the proportion of a population that has had infection at various time points is essential for understanding the dynamics of an epidemic in a particular area.

Puducherry district, population ≈1.25 million, is located in southern India. Its earliest recorded case of COVID-19 was in March 2020; it had 7 total cases by the end of May, 67 by end of June, and 663 by end of July 2020 (4). The district followed national COVID-19 management guidelines, including testing all symptomatic persons and their high-risk contacts.

Figure

Prevalence of severe acute respiratory syndrome coronavirus 2 infection in 3 surveys in Puducherry district, India, 2020. Arrows indicate the timepoint 2 weeks before the midpoint of each of 3 surveillance periods.

Figure. Prevalence of severe acute respiratory syndrome coronavirus 2 infection in 3 surveys in Puducherry district, India, 2020. Arrows indicate the timepoint 2 weeks before the midpoint of each of 3...

We conducted 3 community-based serologic surveys for SARS-CoV-2 antibodies in Puducherry at 1-month intervals, i.e., during August 11–16, September 10–16, and October 12–16, 2020 (Figure). Each survey included 900 adults selected using a multistage sampling procedure. In the initial stages, we chose 30 clusters, including 21 of 90 urban wards and 9 of 62 villages, using a probability proportional to size with replacement method; this method replicated the urban-to-rural ratio (70:30) of the district’s population. Thereafter, in each cluster, we chose 30 households by systematic random sampling; we collected blood from 1 adult (>18 years of age) in each household using a modified Kish method (5,6). The data from these surveys represent the cumulative proportion of population in Puducherry who had been infected with SARS-CoV-2 at ≈2 weeks before midpoint of each survey, i.e., at the end of July, August, and September 2020 (Figure). We obtained approval from Jawaharlal Institute’s ethics committee and informed written consent from participants.

We tested all serum specimens using a commercial electrochemiluminescence-based microparticle immunoassay with 99.5% sensitivity and 99.8% specificity (Elecsys Anti-SARS-CoV-2; Roche, https://www.roche.com) (7) for qualitative detection of antibodies against recombinant nucleoprotein antigen of SARS-CoV-2, following manufacturer’s instructions. Specimens with cutoff index >1.0 were considered seroreactive; cutoff index was the ratio of chemiluminescence signal of sample with that of the reference sample. For each timepoint, we calculated crude prevalence rate with 95% CI using a binomial model. In addition, we used the data on cumulative cases and deaths recorded until each timepoint (4) to calculate infection-to-case and infection-to-death ratios.

We visited 890 households and recruited 869 participants (response rate 97.8%) in August, 902 households from which we recruited 898 (99.8%) participants in September, and 900 households from which we recruited 900 (100%) participants in October. We tracked cumulative number of reported cases (cumulative incidence rates) of COVID-19 and deaths due to the disease in the district at each timepoint (Table) (4). In each survey, the median age was in the mid-40s with nearly equal numbers of men and women. Crude seroprevalence of SARS-CoV-2 antibodies increased from 4.9% (95% CI, 3.5%–6.4%) in August, to 20.7% (18.0%–23.3%) in September, to 34.5% (31.5%–37.7%) in October. These rates indicate that ≈16% of the district’s population acquired SARS-CoV-2 infection during August and ≈14% during September 2020. These rates are much higher than those reported from other parts of the world (8), but are similar to a high seropositivity rate of 57% reported in slum areas of Mumbai (9).

The infection-to-case ratios were similar across the 3 surveys: 19.6 in August, 20.0 in September, and 18.0 in October. These results indicated that, despite implementing the strategies of testing all symptomatic persons and of aggressive contact tracing in the district, only a small proportion of SARS-CoV-2 infections had been diagnosed at each timepoint. This contrasts with the data from high-income countries (10) and could be related to the younger age distribution in the population of India, partial immunity due to other prior coronavirus or other infections, or both.

Strengths of our study include representativeness of the population by its random selection procedure and high participation rate; repeat testing in the same primary sampling units to reduce variability over time; and the use of an assay with high sensitivity and specificity. Limitations included the possibility that some persons did not show development of antibodies following infection, leading to a falsely low seroprevalence; possible loss of antibodies over time, leading to a falsely low rise of seroprevalence with time; and dependence of seroprevalence on the assay used.

Our data indicate a high rate of transmission of SARS-CoV-2 in Puducherry during August and September 2020, with some evidence of slowing over time. By the end of September, nearly one third of the population were infected with SARS-CoV-2, a much larger proportion than those diagnosed with COVID-19. These findings should help guide the response to COVID-19 in our district.

Dr. Kar is an additional professor of preventive and social medicine at the Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. His research interests include disease epidemiology.

Top

Acknowledgments

We thank the members of our survey and laboratory teams, and the study participants for their help.

This project was funded by an intramural grant from the Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.

Top

References

  1. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (‎‎‎‎COVID-19)‎ ‎‎‎ infection, 26 May 2020. 2020 [cited 2020 Aug 24]. https://apps.who.int/iris/handle/10665/332188
  2. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2018 (COVID-19). 2020 [cited 2020 Aug 24]. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
  3. Varghese  GM, John  R, Manesh  A, Karthik  R, Abraham  OC. Clinical management of COVID-19. Indian J Med Res. 2020;151:40110. DOIPubMedGoogle Scholar
  4. Health Department. Puducherry. COVID-19 Puducherry. 2020 [cited 2020 Oct 10]. https://covid19dashboard.py.gov.in
  5. Lavrakas  P. Kish selection method. In: Encyclopedia of survey research methods. 2020 Oct 30 [cited 2020 Nov 30]. https://methods.sagepub.com/reference/encyclopedia-of-survey-research-methods/n262.xml
  6. Kumar  MS, Bhatnagar  T, Manickam  P, Kumar  VS, Rade  K, Shah  N, et al. National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance. Indian J Med Res. 2020;151:41923. DOIPubMedGoogle Scholar
  7. Roche Diagnostics. Elecsys Anti-SARS-CoV-2. 2020 [cited 2020 Oct 10]. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html
  8. Lai  C-C, Wang  J-H, Hsueh  P-R. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020;101:31422. DOIPubMedGoogle Scholar
  9. Tata Institute of Fundamental Research. Technical details: SARS-CoV2 serological survey in Mumbai by NITI-BMC-TIFR. 2020 [cited 2020 Nov 4]. https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI.pdf
  10. Stringhini  S, Wisniak  A, Piumatti  G, Azman  AS, Lauer  SA, Baysson  H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:3139. DOIPubMedGoogle Scholar

Top

Figure
Table

Top

Cite This Article

DOI: 10.3201/eid2702.204480

Original Publication Date: January 14, 2021

Table of Contents – Volume 27, Number 2—February 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Sitanshu Sekhar Kar, Jawaharlal Institute of Postgraduate Medical Education—Preventive and Social Medicine, JIPMER Campus, Puducherry, Puducherry 605006 India

Send To

10000 character(s) remaining.

Top

Page created: December 10, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external